Healthcare: Are These Beaten-Down Clinical-Stage Biotechs Buys?

Industry Focus - A podcast by The Motley Fool

Categories:

Business

Geron shares tumbled after J&J jilted them and Omeros  shares fell sharply following a clinical-trial update. Should you avoid these stocks, or are they bargain bin stocks worth buying? GERN OMER INCY